Articles by Rachel M. Layman
86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1
ByBarbara Pistilli,Rachel M. Layman,Giuseppe Curigliano,Massimo Cristofanilli, MD,Robert Wesolowski,Hyo S Han,Antonio Giordano,Igor Gorbatchevsky,Sara A. Hurvitz, MD Gedatolisib combinations significantly extend progression-free survival after CDK4/6 inhibitor failure in HR+/HER2– breast cancer, with manageable adverse effects and stable quality of life.
87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1
BySara A. Hurvitz, MD,Rachel M. Layman,Giuseppe Curigliano,Massimo Cristofanilli, MD,Robert Wesolowski,Hyo S Han,Antonio Giordano,Igor Gorbatchevsky,Barbara Pistilli 104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapy
ByKevin Kalinsky, MD, MS,Rachel M. Layman,Antonio Giordano,Toru Mukohara,Yeon Hee Park,Geoffrey J. Lindeman,Giampaolo Bianchini,Alexandre de Nonneville,Véronique Diéras, MD,Sherko Kuemmel,Shusen Wang,Zhiming Shao,Sean Kent,Griffith M. Davis,Meng Li,Mafalda Oliveira 105 Real-World Overall Survival With Palbociclib Plus an Aromatase Inhibitor (AI) in Overweight/Obese Patients With HR+/HER2− Metastatic Breast Cancer (MBC)
ByAdam M. Brufsky, MD, PhD,Neil M. Iyengar, MD,Xianchen Liu,Benjamin Li,Doris Makari,Lynn McRoy,Aaron B. Cohen,Melissa Estevez,Vandana G. Abramson,Rachel M. Layman,Giuseppe Curigliano 106 Treatment Durations, Subsequent Treatments, and Switching of First-Line Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with HR+/HER2− Metastatic Breast Cancer in US Routine Clinical Practice
ByAdam M. Brufsky, MD, PhD,Rachel M. Layman,Xianchen Liu,Benjamin Li,Lynn McRoy,Aaron B. Cohen,Melissa Estevez,Paul Cottu,Marc Thill,Giuseppe Curigliano,Hope S. Rugo, MD 124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer
ByHope S. Rugo, MD,Adam M. Brufsky, MD, PhD,Rachel M. Layman,Xianchen Liu,Benjamin Li,Lynn McRoy,Aaron B. Cohen,Melissa Estevez,Paul Cottu,Marc Thill,Giuseppe Curigliano 
10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)
ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Doris Makari,Rachel M. Layman,Hope S. Rugo, MD 
